MR, OPK, CTRX And DGX, 4 Health Services Stocks Pushing The Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 71 points (0.4%) at 16,428 as of Thursday, Dec. 26, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,679 issues advancing vs. 1,241 declining with 183 unchanged.

The Health Services industry currently sits up 0.2% versus the S&P 500, which is up 0.3%. A company within the industry that increased today was Express Scripts ( ESRX), up 0.9%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Mindray Medical International Limited ADR r ( MR) is one of the companies pushing the Health Services industry lower today. As of noon trading, Mindray Medical International Limited ADR r is down $1.13 (-3.0%) to $36.30 on average volume. Thus far, 428,353 shares of Mindray Medical International Limited ADR r exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $36.30-$37.75 after having opened the day at $37.75 as compared to the previous trading day's close of $37.43.

Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International Limited ADR r has a market cap of $4.5 billion and is part of the health care sector. Shares are up 14.5% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Mindray Medical International Limited ADR r a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Mindray Medical International Limited ADR r as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Mindray Medical International Limited ADR r Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Opko Health ( OPK) is down $0.16 (-1.8%) to $8.88 on light volume. Thus far, 1.0 million shares of Opko Health exchanged hands as compared to its average daily volume of 5.6 million shares. The stock has ranged in price between $8.82-$8.99 after having opened the day at $8.93 as compared to the previous trading day's close of $9.04.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Opko Health has a market cap of $3.7 billion and is part of the health care sector. Shares are up 87.9% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Catamaran ( CTRX) is down $0.33 (-0.7%) to $47.90 on light volume. Thus far, 177,079 shares of Catamaran exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $47.56-$48.38 after having opened the day at $48.05 as compared to the previous trading day's close of $48.23.

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $9.9 billion and is part of the health care sector. Shares are up 2.4% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Catamaran a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, impressive record of earnings per share growth and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Catamaran Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Quest Diagnostics ( DGX) is down $0.42 (-0.8%) to $54.08 on light volume. Thus far, 340,461 shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $53.83-$54.44 after having opened the day at $54.43 as compared to the previous trading day's close of $54.50.

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. Quest Diagnostics has a market cap of $7.9 billion and is part of the health care sector. Shares are down 6.5% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Quest Diagnostics a buy, 4 analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, increase in net income, notable return on equity, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Quest Diagnostics Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec